Global Biopharmaceutical Contract Manufacturing Market 2022-2028

August 2022 | 71 pages | ID: GF2DE9624239EN
Gen Consulting Company

Abstracts

The global biopharmaceutical contract manufacturing market market is projected to rise by USD 9 billion by 2028, according to a new report by Gen Consulting Company. It is anticipated to expand at a CAGR of 8.9 percent during the forecast period.

The report provides in-depth analysis and insights regarding the current global market scenario, latest trends and drivers into global biopharmaceutical contract manufacturing market. It offers an exclusive insight into various details such as market size, key trends, competitive landscape, growth rate and market segments. This study also provides an analysis of the impact of the COVID-19 crisis on the biopharmaceutical contract manufacturing industry.

This industry report offers market estimates and forecasts of the global market, followed by a detailed analysis of the product, service, source, organization size, and region. The global market for biopharmaceutical contract manufacturing can be segmented by product: biologics, biosimilars. The biologics segment held the largest revenue share in 2021. Biopharmaceutical contract manufacturing market is further segmented by service: analytical and QC studies, fill and finish operations, packaging, process development. Based on source, the biopharmaceutical contract manufacturing market is segmented into: mammalian, microbial-based biologics/non-mammalian. The mammalian segment captured the largest share of the market in 2021. On the basis of organization size, the biopharmaceutical contract manufacturing market also can be divided into: large enterprises, small and medium-sized enterprises (SMEs). According to the research, the large enterprises segment had the largest share in the global biopharmaceutical contract manufacturing market. Biopharmaceutical contract manufacturing market by region is categorized into: North America, Europe, Asia-Pacific, Rest of the World.

By product:

• biologics
• biosimilars

By service:

• analytical and QC studies
• fill and finish operations
• packaging
• process development

By source:

• mammalian
• microbial-based biologics/non-mammalian

By organization size:

• large enterprises
• small and medium-sized enterprises (SMEs)

By region:

• North America
• Europe
• Asia-Pacific
• Rest of the World

The biologics market is further segmented into monoclonal antibodies (mAbs), recombinant proteins, vaccines, others. Globally, the mAbs segment made up the largest share of the biopharmaceutical contract manufacturing market.

The report has also analysed the competitive landscape of the global biopharmaceutical contract manufacturing market with some of the key players being AbbVie, Inc., Ajinomoto Co. Inc., Boehringer Ingelheim Biopharmaceuticals GmbH, Catalent, Inc., Emergent BioSolutions Inc., FUJIFILM Holdings Corporation, Lonza Group AG, Merck KGaA, Pfizer Inc., Samsung Biologics Co., Ltd., Serum Institute Of India Pvt. Ltd., Thermo Fisher Scientific, Inc., WuXi Biologics, Inc., among others.

*REQUEST FREE SAMPLE TO GET A COMPLETE LIST OF COMPANIES

Historical & Forecast Period

This research report provides analysis for each segment from 2018 to 2028 considering 2021 to be the base year.

Scope of the Report

• To analyze and forecast the market size of the global biopharmaceutical contract manufacturing market.
• To classify and forecast the global biopharmaceutical contract manufacturing market based on product, service, source, organization size, region.
• To identify drivers and challenges for the global biopharmaceutical contract manufacturing market.
• To examine competitive developments such as mergers & acquisitions, agreements, collaborations and partnerships, etc., in the global biopharmaceutical contract manufacturing market.
• To identify and analyze the profile of leading players operating in the global biopharmaceutical contract manufacturing market.

Why Choose This Report

• Gain a reliable outlook of the global biopharmaceutical contract manufacturing market forecasts from 2022 to 2028 across scenarios.
• Identify growth segments for investment.
• Stay ahead of competitors through company profiles and market data.
• The market estimate for ease of analysis across scenarios in Excel format.
• Strategy consulting and research support for three months.
• Print authentication provided for the single-user license.

Contents

PART 1. INTRODUCTION

Report description
Objectives of the study
Market segment
Years considered for the report
Currency
Key target audience

PART 2. METHODOLOGY

PART 3. EXECUTIVE SUMMARY

PART 4. MARKET OVERVIEW

Introduction
Drivers
Restraints
Impact of COVID-19 pandemic

PART 5. MARKET BREAKDOWN BY PRODUCT

Biologics
Biosimilars

PART 6. MARKET BREAKDOWN BY SERVICE

Analytical and QC studies
Fill and finish operations
Packaging
Process development

PART 7. MARKET BREAKDOWN BY SOURCE

Mammalian
Microbial-based biologics/non-mammalian

PART 8. MARKET BREAKDOWN BY ORGANIZATION SIZE

Large enterprises
Small and medium-sized enterprises (SMEs)

PART 9. MARKET BREAKDOWN BY REGION

North America
Europe
Asia-Pacific
Rest of the World

PART 10. KEY COMPANIES

AbbVie, Inc.
Ajinomoto Co. Inc.
Boehringer Ingelheim Biopharmaceuticals GmbH
Catalent, Inc.
Emergent BioSolutions Inc.
FUJIFILM Holdings Corporation
Lonza Group AG
Merck KGaA
Pfizer Inc.
Samsung Biologics Co., Ltd.
Serum Institute Of India Pvt. Ltd.
Thermo Fisher Scientific, Inc.
WuXi Biologics, Inc.
*REQUEST FREE SAMPLE TO GET A COMPLETE LIST OF COMPANIES
DISCLAIMER